Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2018 (2018), Article ID 9803851, 9 pages
https://doi.org/10.1155/2018/9803851
Research Article

Association between Low Free Triiodothyronine Levels and Poor Prognosis in Patients with Acute ST-Elevation Myocardial Infarction

1Department of Cardiology, Xinqiao Hospital, Third Military Medical University, Chongqing 400037, China
2PLA Institute of Cardiovascular Disease, Chongqing 400037, China

Correspondence should be addressed to Lan Huang; nc.ude.ummt@gnauhl

Received 2 November 2017; Revised 16 January 2018; Accepted 23 January 2018; Published 16 April 2018

Academic Editor: Ramazan Akdemir

Copyright © 2018 Yuanbin Song et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background. Low free triiodothyronine (fT3) levels are generally associated with poor prognosis in patients with heart diseases, but this is controversial and there is a lack of data about ST-elevation myocardial infarction (STEMI) in Chinese patients. Objective. To assess the association between fT3 levels and the prognosis of patients with STEMI. Methods. This was a prospective observational study of 699 consecutive patients with STEMI treated at the Xinqiao Hospital between January 1, 2013, and December 31, 2014. The patients were divided into the low fT3 (fT3 < 3.1 pmol/L; , 27.5%) and normal fT3 (fT3 ≥ 3.1 pmol/L; , 72.5%) groups according to fT3 levels at admission. Patients were followed up at 1, 3, 6, and 12 months for all-cause death and major adverse cardiac events (MACE). Results. During the 1-year follow-up, there were 70 all-cause deaths (39.1%) in the low fT3 group and 40 (8.5%) in the normal fT3 group (). MACE occurred in 105 patients (58.7%) in the low fT3 group and 74 (15.6%) in the normal fT3 group (). Multivariate Cox proportional hazards regression analysis indicated that fT3 levels were independently associated with 30-day and 1-year all-cause death [30-day: hazard ratio (HR) = 0.702, 95% confidence interval (95% CI): 0.501–0.983, ; 1-year: HR = 0.557, 95% CI: 0.411–0.755, ] and MACE (30-day: HR = 0.719, 95% CI: 0.528–0.979, ; 1-year: HR = 0.557, 95% CI: 0.445–0.698, ). Conclusion. Low fT3 levels were strongly associated with poor prognosis in patients with STEMI. Measurement of fT3 levels may be a valuable and simple way to identify high-risk STEMI patients.